데이터가 없습니다.

1. Response to atezolizumab plus bevacizumab specific for lung and lymph node metastases affects survival of patients with HCC [ LIVER INTERNATIONAL ] - 2024.04.01
2. Loco-regional therapies competing with radiofrequency ablation in potential indications for hepatocellular carcinoma : a network meta-analysis [ Clinical and Molecular Hepatology ] - 2023.10.01
3. Clinicogenomic characteristics and synthetic lethal implications of germline homologous recombination? deficient hepatocellular carcinoma [ HEPATOLOGY ] - 2023.08.01
4. Treatment patterns for hepatocellular carcinoma in patients with Child?Pugh class B and their impact on survival: A Korean nationwide registry study [ LIVER INTERNATIONAL ] - 2022.12.01
5. Ranking of Transarterial and Targeted Therapies for Advanced HCC: A Network Meta-Analysis of Sorafenib-Controlled Trials [ Hepatology Communications ] - 2022.10.01
6. Postresection Period-Specific Hazard of Recurrence as a Framework for Surveillance Strategy in Patients with Hepatocellular Carcinoma: A Multicenter Outcome Study [ LIVER CANCER ] - 2022.09.17
7. Extrahepatic carcinogenicity of oral nucleos(t)ide analogues in chronic hepatitis B carriers: A 35,000-Korean outcome study [ JOURNAL OF VIRAL HEPATITIS ] - 2022.09.01
8. Role of the alpha-fetoprotein response in immune checkpoint inhibitor-based treatment of patients with hepatocellular carcinoma [ JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY ] - 2022.08.01
9. Integrated prognostic and histogenomic justification of stage-directed therapy for single large hepatocellular carcinoma: a Korean nationwide registry study [ GUT ] - 2022.06.01
10. PET-Based Radiogenomics Supports mTOR Pathway Targeting for Hepatocellular Carcinoma [ CLINICAL CANCER RESEARCH ] - 2022.05.01
11. Comprehensive characterization of viral integrations and genomic aberrations in HBV?infected intrahepatic cholangiocarcinomas [ HEPATOLOGY ] - 2022.04.01
12. Cervicocerebral atherosclerosis and its hepatic and coronary risk factors in patients with liver cirrhosis [ CLINICAL AND MOLECULAR HEPATOLOGY ] - 2022.01.01
13. Prognostic Molecular Indices of Resectable Hepatocellular Carcinoma: Implications of S100P for Early Recurrence [ ANNALS OF SURGICAL ONCOLOGY ] - 2021.10.01
14. Dynamics of Serum Retinol and Alpha-Tocopherol Levels According to Non-Alcoholic Fatty Liver Disease Status [ NUTRIENTS ] - 2021.06.19
15. Variceal bleeding is aggravated by portal venous invasion of hepatocellular carcinoma: a matched nested case-control study [ BMC CANCER ] - 2021.01.09
16. Continued value of the serum alpha-fetoprotein test in surveilling at-risk populations for hepatocellular carcinoma [ PLOS ONE ] - 2020.08.26
17. Hepatocyte-Specific Magnetic Resonance Imaging?Based Assessment of Indeterminate Hepatic Nodules in the Liver Transplant Evaluation of Patients With Cirrhosis [ LIVER TRANSPLANTATION ] - 2020.03.01
18. The clinical behavior and survival of patients with hepatocellular carcinoma and a family history of the disease [ Cancer Medicine ] - 2019.11.01
19. Immunogenomic landscape of hepatocellular carcinoma with immune cell stroma and EBV-positive tumor-infiltrating lymphocytes [ JOURNAL OF HEPATOLOGY ] - 2019.07.01
20. A Prospective Evaluation of the Reliability and Utility of Quality of Life Measures in Patients With Hepatocellular Carcinoma [ AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS ] - 2019.07.01
21. Histological expression of methionine adenosyl transferase (MAT) 2A as a post-surgical prognostic surrogate in patients with hepatocellular carcinoma [ JOURNAL OF SURGICAL ONCOLOGY ] - 2018.04.01
22. Chronic hepatitis B infection and non-hepatocellular cancers: A hospital registry-based, case-control study [ PLOS ONE ] - 2018.03.15
23. Risks Versus Benefits of Anticoagulation for Atrial Fibrillation in Cirrhotic Patients [ JOURNAL OF CARDIOVASCULAR PHARMACOLOGY ] - 2017.10.01
24. Prognostic Scoring Models for Patients Undergoing Sorafenib Treatment for Advanced Stage Hepatocellular Carcinoma in Real-Life Practice [ AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS ] - 2017.04.01
25. Role of computed tomography volumetry in estimating liver weights in surgical subjects with hepatic steatosis. [ Experimental and Clinical Transplantation ] - 2017.04.01
26. Clinical validity of Metroticket calculator in transplant patients undergoing prior chemoembolization for hepatocellular carcinoma [ HEPATOLOGY INTERNATIONAL ] - 2017.03.01
27. Comprehensive outcomes of on- and off-antiviral prophylaxis in hepatitis B patients undergoing cancer chemotherapy: A competing risks analysis. [ JOURNAL OF MEDICAL VIROLOGY ] - 2016.09.01
28. Risk prediction for patients with hepatocellular carcinoma undergoing chemoembolization: development of a prediction model [ LIVER INTERNATIONAL ] - 2016.01.01
29. Radiofrequency ablation as an alternative to hepatic resection for single small hepatocellular carcinomas. [ BRITISH JOURNAL OF SURGERY ] - 2016.01.01
30. A Patient-Based Nomogram for Predicting Overall Survival after Radiofrequency Ablation for Hepatocellular Carcinoma [ JOURNAL OF VASCULAR AND INTERVENTIONAL RADIOLOGY ] - 2015.12.01
31. Intimate association of visceral obesity with non-alcoholic fatty liver disease in healthy Asians: A case-control study [ JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY ] - 2015.11.01
32. Nomograms for Predicting Outcomes after Chemoembolization in Patients with Nonmetastatic Hepatocellular Carcinoma. [ JOURNAL OF VASCULAR AND INTERVENTIONAL RADIOLOGY ] - 2015.08.01
33. Prognostic nomograms for prediction of recurrence and survival after curative liver resection for hepatocellular carcinoma. [ ANNALS OF SURGERY ] - 2015.05.01
34. Optimal methods for measuring eligibility for liver transplant in hepatocellular carcinoma patients undergoing transarterial chemoembolization. [ JOURNAL OF HEPATOLOGY ] - 2015.05.01
35. Prognostic performance of preoperative gadoxetic acid-enhanced MRI in resectable hepatocellular carcinoma. [ JOURNAL OF MAGNETIC RESONANCE IMAGING ] - 2015.04.01
36. Comparison of Chemoembolization with and without Radiation Therapy and Sorafenib for Advanced Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis: A Propensity Score Analysis [ JOURNAL OF VASCULAR AND INTERVENTIONAL RADIOLOGY ] - 2015.03.01
37. Genomic portrait of resectable hepatocellular carcinomas: Implications of RB1 and FGF19 aberrations for patient stratification [ HEPATOLOGY ] - 2014.12.01
38. Clinicobiochemical prediction of biopsy-proven cases of severe hepatic fibrosis in patients with chronic hepatitis C infection. [ BMJ OPEN ] - 2014.11.03
39. Prevalence and prediction of coronary artery disease in patients with liver cirrhosis: a registry-based matched case-control study. [ CIRCULATION ] - 2014.10.01
40. Clinical significance of the best response during repeated transarterial chemoembolization in the treatment of hepatocellular carcinoma [ JOURNAL OF HEPATOLOGY ] - 2014.06.02
41. Assessment of current criteria for primary nonresponse in chronic hepatitis B patients receiving entecavir therapy. [ HEPATOLOGY ] - 2014.04.01
42. Clinical appraisal of the recently proposed Barcelona Clinic Liver Cancer stage B subclassification by survival analysis. [ JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY ] - 2014.04.01
43. Clinical implications of preoperative and intraoperative liver biopsies for evaluating donor steatosis in living related liver transplantation. [ LIVER TRANSPLANTATION ] - 2014.04.01
44. Prognostic value of hepatocyte nuclear factors 4α and 1α identified by tissue microarray in resectable hepatocellular carcinoma. [ JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY ] - 2014.03.03
45. Sorafenib Alone versus Sorafenib Combined with Transarterial Chemoembolization for Advanced-Stage Hepatocellular Carcinoma: Results of Propensity Score Analyses. [ RADIOLOGY ] - 2013.11.01
46. Clinical Usefulness of Endoscopic Palliation in Patients with Biliary Obstruction Caused by Hepatocellular Carcinoma [ DIGESTION ] - 2013.10.01
47. Half-life of serum alpha-fetoprotein: an early prognostic index of recurrence and survival after hepatic resection for hepatocellular carcinoma [ ANNALS OF SURGERY ] - 2013.04.01
48. Hepatocyte nuclear factor 1β is a novel prognostic marker independent of the milan criteria in transplantable hepatocellular carcinoma: A retrospective analysis based on tissue microarrays [ LIVER TRANSPLANTATION ] - 2013.03.15
49. Optimal measurement modality and method for evaluation of responses to transarterial chemoembolization of hepatocellular carcinoma based on enhancement criteria. [ JOURNAL OF VASCULAR AND INTERVENTIONAL RADIOLOGY ] - 2013.03.01
50. Clinical Implications of Arrest-Defective Protein 1 Expression in Hepatocellular Carcinoma: A Novel Predictor of Microvascular Invasion [ DIGESTIVE DISEASES ] - 2012.12.31
51. Is serum alpha-fetoprotein useful for predicting recurrence and mortality specific to hepatocellular carcinoma after hepatectomy? A test based on propensity scores and competing risks analysis [ ANNALS OF SURGICAL ONCOLOGY ] - 2012.11.01
52. Clinical utility of des-γ-carboxyprothrombin kinetics as a complement to radiologic response in patients with hepatocellular carcinoma undergoing transarterial chemoembolization [ JOURNAL OF VASCULAR AND INTERVENTIONAL RADIOLOGY ] - 2012.07.31
53. Relationship of HLA-DRB1 Alleles With Hepatocellular Carcinoma Development in Chronic Hepatitis B Patients [ JOURNAL OF CLINICAL GASTROENTEROLOGY ] - 2012.04.16
54. Which response criteria best help predict survival of patients with hepatocellular caricnoma following chemoembolization? A validation study of old and new models. [ RADIOLOGY ] - 2012.02.15
55. Maximum number of target lesions required to measure responses to transarterial chemoembolization using the enhancement criteria in patients with intrahepatic hepatocellular carcinoma [ JOURNAL OF HEPATOLOGY ] - 2012.02.15
56. HLA-DRB1 * 010101 Allele Is Closely Associated with Poor Virological Response to Lamivudine Therapy in Patients with Chronic Hepatitis B [ DIGESTION ] - 2011.12.01
57. Suppressive effects of entecavir on hepatitis B virus and hepatocellular carcinoma [ JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY ] - 2011.09.01
58. Estimation of the Healthy Upper Limits for Serum Alanine Aminotransferase in Asian Populations with Normal Liver Histology [ HEPATOLOGY ] - 2010.05.01
59. Efficacy of entecavir in treatment-naïve patients with hepatitis B virus-related decompensated cirrhosis [ JOURNAL OF HEPATOLOGY ] - 2010.02.01
60. Complete Necrosis After Transarterial Chemoembolization Could Predict Prolonged Survival in Patients with Recurrent Intrahepatic Hepatocellular Carcinoma After Curative Resection [ ANNALS OF SURGICAL ONCOLOGY ] - 2010.01.01

1. RB1 돌연변이 간세포암의 분자유전학적 특징 고찰 및 타겟 발굴을 통한 신약개발 - 2023.03.01 ~ 2024.10.31
2. 지방간을 동반한 만성 B형 간염에 의한 중등도 이상의 간섬유화 환자에서 스타틴_에제티미브 복합제 사용이 간세포암종 발생에 미치는 영향에 관한 다기관, 무작위 배정, 개방, 전향적 비교연구 - 2022.04.04 ~ 2027.08.31
3. 원발성 간암에서 B형간염 바이러스에 의한 삽입성 변이 유발을 억제하는 항바이러스_항암 치료제의 실험적 개발 및 임상적 적용 - 2022.03.01 ~ 2023.02.28
4. RB1 돌연변이 간세포암의 분자유전학적 특징 고찰 및 타겟 발굴을 통한 신약 개발 - 2021.11.01 ~ 2024.08.31
5. (2017, 전략) 통합 유전체 분석을 통한 바이러스성 또는 염증성 원발 간암 발생 과정의 규명 및 암의 발생과 진행에 연관된 타겟 제어 기술의 확립 - 2021.03.01 ~ 2021.10.31
6. 면역항암제 기반의 항암요법을 시행하는 진행성 간세포암 환자에서 유전체 및 면역 프로파일링 분석을 통한 치료 반응 및 내성 연관 예측 바이오마커 및 타겟 발굴 - 2020.06.11 ~ 2025.12.31
7. DNA 손상 복구 기전 결핍이 있는 원발성 간암의 유전체적 특징 규명 및 치료타겟 발굴을 위한 in vitro 및 in vivo 연구 - 2020.05.01 ~ 2023.04.30
8. 통합 유전체 분석을 통한 바이러스성 또는 염증성 원발 간암 발생 과정의 규명 및 암의 발생과 진행에 연관된 타겟 제어 기술의 확립 - 2020.03.01 ~ 2021.02.28
9. 통합 유전체 분석을 통한 바이러스성 또는 염증성 원발 간암 발생 과정의 규명 및 암의 발생과 진행에 연관된 타겟 제어 기술의 확립 - 2019.03.01 ~ 2020.02.29
10. 간세포암종 원인인자에 따른 종양미세환경의 면역유전체학적 특성과 이와 연관된 면역항암제 반응 및 내성의 기전 규명을 위한 연구 - 2018.10.01 ~ 2020.09.30
11. 근치적 간 절제술 또는 제거술 이후 재발 위험성이 높은 간세포암이 있는 시험대상자에서 위약 대비 니볼루맙 보조요법에 대한 제3상, 무작위배정, 이중 눈가림 임상시험 - 2018.05.16 ~ 2025.09.30
12. 원발성 간암의 유전체-전사체 분석을 통한 면역 유전학적 발암 기전 규명 및 바이오마커 발굴 - 2018.04.01 ~ 2021.12.31
13. 통합 유전체 분석을 통한 바이러스성 또는 염증성 원발 간암 발생 과정의 규명 및 암의 발생과 진행에 연관된 타겟 제어 기술의 확립 - 2018.03.01 ~ 2019.02.28
14. In Vitro 분석을 토대로 암환자 이종 이식 모델을 이용하여 간세포암에서 소라페닙 일차 및 획득 내성을 극복하기 위한 신약 후보 물질 발굴 및 치료 전략 수립에 관한 연구 - 2018.01.01 ~ 2018.12.31
15. 통합 유전체 분석을 통한 바이러스성 또는 염증성 원발 간암 발생 과정의 규명 및 암의 발생과 진행에 연관된 타겟 제어 기술의 확립 - 2017.11.01 ~ 2018.02.28
16. In Vitro 분석을 토대로 암환자 이종 이식 모델을 이용하여 간세포암에서 소라페닙 일차 및 획득 내성을 극복하기 위한 신약 후보 물질 발굴 및 치료 전략 수립에 관한 연구 - 2017.01.01 ~ 2017.12.31
17. 간세포암 환자에서 환자 유래 종양 이종 이식 모델의 개발 - 2016.12.01 ~ 2019.05.31
18. 간세포암 환자에서 환자 유래 종양 이종 이식 모델의 개발 - 2016.08.29 ~ 2018.06.30
19. 간세포암의 진행에 대해 RB gene이 미치는 영향에 대한 in vitro 및 in vivo 연구 - 2016.01.01 ~ 2020.12.31
20. 간세포암에서 sorafenib 내성 기전 확인 및 고효율 약효 분석을 이용한 sorafenib 내성 극복 및 복합치료요법 - 2016.01.01 ~ 2016.12.31
21. 간세포암에서 sorafenib 내성 기전 확인 및 고효율 약효 분석을 이용한 sorafenib 내성 극복 및 복합치료요법 - 2015.01.01 ~ 2015.12.31
22. 만성 B형 간접 관련 간세포암에서 새로운 바이오마커 발굴을 위한 단백체학(proteomics) 분석 연구 - 2012.11.01 ~ 2013.10.31
23. 치료를 받은 적이 없는 유전자1형, C형 간염 환자를 대상으로 peginterferon alfa­2a와 ribavirin이 포함된 치료 요법의 일부로서 TMC435 대비 위약의 유효성, 약동학, 안… - 2012.09.17 ~ 2015.03.31
24. 라미부딘 내성 만성 B형간염 환자에서 HLA-DRB1 유전자의 다형성과 아데포비어 구제 요법의 치료 반응 및 간세포암 발생과의 연관성-2차년도 - 2011.05.01 ~ 2012.04.30
25. 라미부딘 내성 만성 B형간염 환자에서 HLA-DRB1 유전자의 다형성과 아데포비어 구제 요법의 치료 반응 및 간세포암 발생과의 연관성 - 2010.05.01 ~ 2011.04.30

데이터가 없습니다.

      데이터가 없습니다.

 공지